Exhibit 99.2

OraSure Technologies, Inc.

2017 First Quarter

Analyst/Investor Conference Call

May 3, 2017

Prepared Remarks of Douglas A. Michels and Ronald H. Spair

Please see “Important Information” at the conclusion of the following prepared remarks.

Introduction – Doug Michels

Thank you Michelle. Good afternoon everyone and welcome to our call.

I am very pleased to report that we delivered another strong quarter and the year is off to a terrific start. Demand for our products is strong and we are excited about the future prospects for our business.

On last quarters’ call, I encouraged those who missed our Analyst Day in November 2016 to consider reviewing our commentary from that day. It provides a helpful roadmap of the numerous opportunities available in our various businesses. As you will hear today, we are making great progress on the opportunities we highlighted at the Analyst Day. One of our goals was to communicate to the investment community why we believe OraSure is in the early stages of several large market opportunities and very well positioned to capitalize on them. One example which I am happy to share this afternoon, is the recent signing of, another large contract, this time with a genomics customer, to supply them with over $20 million of our molecular collection devices over a period greater than 12 months. This is the largest contract in the history of our molecular business. There is no shortage of potential opportunities and we are pursuing them across our business.

So, moving on to the quarter, as indicated in our earnings release, we delivered a strong first quarter.

So with that brief introduction, let me turn the call over to Ron for his financial review. I will then provide some business updates, after which we will take your questions.

Ron...

First Quarter 2017 Financial Results – Ron Spair

Thanks Doug, and good afternoon everyone.

Revenues – Ron Spair

We certainly are off to a great start for 2017. Our first quarter consolidated net revenues increased 12% to $32.5 million, compared to $29.1 million reported in the first quarter of 2016. Notably, our consolidated net product revenues rose 25% to $31.4 million compared to the prior year period. Higher sales of our molecular products along with higher international sales of our OraQuick^® HIV self-test and OraQuick^® HCV product were partially offset by a decline in domestic sales of our OraQuick^® HIV and HCV products and lower cryosurgical sales.

2

Other Revenues were $1.1 million in the current quarter, representing funding we received from BARDA for our rapid Ebola and Zika products. Other revenues in the first quarter of 2016 totaled $3.8 million and included $482,000 in BARDA funding and $3.4 million of exclusivity revenues under the AbbVie HCV co-promotion agreement which terminated effective December 31, 2016.

Our molecular revenues rose 55% to $10.7 million in the first quarter of 2017 compared to $6.9 million in the first quarter of 2016. Sales of our Oragene^® product to commercial customers increased 119%, largely due to higher customer demand and the increased sales from new customer accounts won in the second half of 2016. Academic sales decreased 20% largely due to customer ordering patterns and the absence of a one-time order of almost $400,000 by the WHO for an epidemiology study which occurred in the first quarter of 2016 and will not repeat in 2017.

International sales of our HCV test in the first quarter of 2017 rose 340% to $4.4 million from $1.0 million in the same period of 2016, primarily due to the continued shipments of product to a foreign government pursuant to a previously announced countrywide elimination program as well as increased shipments for large-scale screening programs. Domestic OraQuick^® HCV product sales decreased 10% in the first quarter of 2017 to $1.7 million from $1.9 million in the prior year period, primarily due to customer ordering patterns.

International sales of our HIV products increased 210% to $2.6 million in the first quarter of 2017, compared to $854,000 in the first quarter of 2017. This increase was due to the continued shipment of product in support of an HIV self-testing program in Africa and higher sales in the Middle East.

Domestic professional HIV sales decreased 33% to $3.8 million in the first quarter of 2017, compared to $5.7 million in the first quarter of 2016, as result of customer ordering patterns and competition from other products.

3

Sales of our cryosurgical products decreased 21% to $3.1 million in the first quarter of 2017 from $3.9 million in the first quarter of 2016 largely due to lower sales of our international OTC products.

Gross Margin – Ron Spair

Gross margin for the first quarter of 2017 was 62% compared to 70% reported for the first quarter of 2016. Margin for the current quarter decreased primarily due to the absence of AbbVie exclusivity revenues in 2017 as a result of the termination of our agreement at the end of 2016, a less favorable product mix, and increased scrap and spoilage costs.

Operating Expenses – Ron Spair

Our consolidated operating expenses for the first quarter of 2017 were $4.4 million compared to $17.6 million in the comparable period of 2016. This decrease was largely due to the inclusion of a $12.5 million pre-tax gain related to our Ancestry litigation settlement, the absence of costs associated with our terminated HCV co-promotion agreement with AbbVie, and lower legal fees.

Income Taxes – Ron Spair

Income tax expense was $3.9 million in the first quarter of 2017 compared to $61,000 in the same period last year. Taxes for the current period included the additional Canadian taxes due as a result of the litigation settlement gain of $12.5 million.

Net Income – Ron Spair

From a bottom line perspective, we reported net income of $12.4 million, or $0.21 per share on a fully diluted basis, for the first quarter of 2017, compared to net income of $2.4 million, or $0.04 per share, for the same period of 2016.

4

Cash Flow from Operations and Liquidity – Ron Spair

Turning briefly to our balance sheet and cash flow, we continue to maintain a solid cash and liquidity position. Our cash and short-term investment balance at March 31, 2017 was $141.5 million compared to $120.9 million at December 31, 2016. Cash generated by operating activities for the first three months of 2017 was $12.6 million compared to $4.7 million in the same period of 2016.

Second Quarter 2017 Consolidated Financial Guidance – Ron Spair

Turning to guidance for the second quarter of 2017, we are projecting consolidated net revenues of approximately $36.5 million to $37.0 million. We are also projecting consolidated net income of approximately $0.07 to $0.08 per share for Q2 of 2017.

And with that, I will now turn the call back over to Doug.

Business Update – Doug Michels

Thanks, Ron. As you know, our growth strategy is focused on our infectious disease business, which includes our HCV, HIV, Ebola, Zika and TB programs, and our molecular business, which includes our genomics and microbiome programs.

Infectious Disease Testing – Doug Michels

The storyline in infectious disease continues to be strong international growth.

HCV Elimination Programs

The largest Q1 revenue increases came from international HCV sales in support of large-scale HCV elimination or testing programs, including the large government supply contract we previously highlighted. That initiative has been going well and we expect to continue supplying product to this government customer throughout the remainder of 2017. In addition, this customer has an option to renew the contract and purchase up to 100% of the original quantities of product on the same terms and conditions as provided in the original contract. We are starting discussions on a potential renewal this week.

5

The level of interest in foreign HCV testing and treatment programs continues to be strong. Orders have been received from two other countries that have indicated an intent to start testing programs. These orders have been filled and we anticipate additional orders from these countries later this year. As we reported during our Analyst Day last November, the WHO has announced its goal of eliminating Hepatitis C by the year 2030. To date, 36 countries have developed national programs to combat hepatitis and 33 additional countries are developing similar plans. While this does not guarantee available funding or that large-scale HCV testing programs will occur in all cases, it does evidence the increased focus by high prevalence countries on the need to take action with respect to hepatitis. We believe this bodes well for the future of our HCV business.

HIV Self Testing

The other main growth driver internationally was our OraQuick^® HIV self-test. We indicated on the last call that an additional order had been received from Population Services International, or “PSI,” in support of the “Self-Testing in Africa,” or STAR project. This additional order was for approximately 350,000 tests and we filled that order during Q1.

To date, we have shipped over 700,000 tests as part of the initial phase of the STAR project. Field reports remain positive on the use and performance of our test and a second phase of this program is now being discussed with PSI and its funding source, UNITAID. We expect more details on the timing and scope of phase II in the next few months, and we expect additional orders throughout 2017 and beyond.

The international focus on HIV self-testing is increasing and the STAR program is just part of the story. In November 2016, UNITAID issued a “call for proposals” for the purpose of accelerating the demand for and widespread adoption of HIV self-testing programs in low and middle income countries. As part of this request, UNITAID specifically mentioned the success of the STAR project that has been using our product. The closing date for submissions to UNITAID was March 31^st.. These additional programs, assuming they are approved and funded, are expected to be incremental to the STAR program.

6

In addition, we continue to see high interest levels from a number of public health departments or ministries and NGO’s in numerous countries. We are currently engaged with approximately 20 countries that have taken or are planning concrete steps to begin implementation of self-testing. These include many countries outside the current STAR pilot program.

During the first quarter, we announced that our HIV self-test was designated as eligible for procurement by purchasing entities entitled to access Global Fund resources. Our product was classified by the Global Fund’s Expert Review Panel for Diagnostics (ERPD) as Category 2, which permits product procurement for 12 months with Global Fund monies. This designation is important in that it permits funded purchases even though our product has not yet received WHO pre-qualification.

On that front, our efforts to obtain pre-qualification have also progressed. During our last call, we indicated that our submission was under active review and we expected to receive feedback during the first quarter. We did receive that feedback and are now in the process of completing additional data collection that we expect to submit to the WHO in early June. WHO pre-qualification is important in that it will enable countries to purchase our test with monies from large funding organizations such as UNITAID, PEPFAR and the Global Fund.

So, we remain very optimistic about HIV self-testing and believe this business will be an important source of future growth for the infectious disease market.

Domestic Business

The strong international sales during the first quarter more than offset declines in our domestic businesses.

7

The magnitude of the Q1 decline in HIV sales was driven primarily by the timing of customer orders, including in particular a very large order from a public health jurisdiction, and by competition. In the past, this jurisdiction has placed their orders during the first quarter. However, beginning in 2017, the customer decided to spread its orders out more evenly throughout the year. While the pressure on our HIV domestic business is expected to continue, we do not anticipate the steep decline in Q1 to repeat in future periods.

Timing of purchases was a key factor in the performance of our domestic HCV business. We remain confident in the future growth of our domestic HCV sales. As public health budgets continue to be pressured, a number of jurisdictions are shifting funding to HCV from other areas of their budget and one of our largest customers recently provided a forecast doubling their deployment of HCV tests in 2017. In addition, as you may know, public health jurisdictions are attempting to respond to the opioid epidemic. Since injection drug use remains the most common risk factor for HCV infection in the United States and, in fact, accounts for more than 50% of all new infections, we are beginning to see drug treatment centers increase deployment of HCV testing programs. As a result, we expect our domestic HCV business to resume more normal revenue patterns and return to year-over-year quarterly growth beginning in Q2.

Tuberculosis

As indicated in our last call, clinical studies using our Tuberculosis product have been completed by the Foundation for Innovative New Diagnostics, or FIND, in support of WHO endorsement of our OMNIgene^®• SPUTUM product. FIND has issued its final data dossier on our product and the WHO has indicated it will review the FIND data and issue a broader review of all commercial sputum transport reagents later this year. In the meantime, commercial discussions with foreign ministries of health for deployment of our product are progressing, as are discussions with a National Tuberculosis and Leprosy Control Program in Africa. These initiatives and other activities are expected to generate expanded sales in 2018.

8

Emerging Diseases

Turning briefly to emerging diseases, there have been a number of activities that continue to progress.

With respect to our OraQuick^® Ebola test, the CDC is currently assessing its product needs for 2017 and we should have better visibility of future orders once that assessment is completed. Our clinical work for this product also continues. We have had further dialog with the FDA and we received input on the additional clinical work needed for 510(k) clearance. We expect this work will result in a mid-year 2018 submission to the FDA.

Finally, our efforts to progress clinical activities for our new Zika test continue. We are still planning to submit for Emergency Use Authorization from the FDA later this year. Zika remains an important public health risk and we believe our new test can play an important role in combatting this disease.

Molecular Business Growth Drivers – Doug Michels

As Ron explained, our molecular business turned in an exceptional Q1 performance, with 55% growth over the prior year quarter and 25% growth sequentially from Q4 of last year. We expect continued strong performance from this part of the business with strong double-digit growth in Q2 from the prior-year quarter.

Genomics

During Q1, there were a number of developments in the genomics market.

9

Microbiome

Turning to our Microbiome business, we recorded almost $800,000 in revenues in Q1, a 373% increase over Q1 of last year. We recorded approximately $1.1 million in microbiome revenues for the full-year 2016, and we expect to exceed that total by the end of Q2.

The majority of our microbiome revenues continue to be derived from our Oragene^® gut or fecal sample collection kits and related services. We acquired 135 new microbiome testers in Q1, a 65% increase over Q1 2016, with the majority of Q1 microbiome revenues coming from academic or research customers.

Not all of the new testers are new customers as we are also seeing increased cross selling of microbiome solutions to existing genomics customers who are expanding their research to include microbiome data. For example, during the quarter, we closed a sale for both gut microbiome kits and our oral microbiome collection kits with a world-renowned research institute which has been an Oragene^® customer for over ten years. We believe our ability to provide trusted solutions for both genomics and microbiome research is a meaningful differentiator for our business. While gut microbiome remains the primary area of interest in this market, we are starting to see more and more interest in other microbiomes, allowing us to deliver increasing value with our portfolio of microbiome collection devices and services.

10

Litigation Settlement

Finally, in February we announced the settlement of our litigation against Ancestry.com and its contract manufacturer. As part of this settlement, Ancestry paid us $12.5 million and we granted Ancestry a royalty bearing, non-exclusive worldwide license to certain of our patents. The license is specifically limited to the saliva DNA collection kits sold or used as part of Ancestry’s genetic testing service offerings and does not cover the sale or use of product outside of its business. We are pleased with the terms of this settlement and are happy to have this matter resolved.

Operations Update – Doug Michels

A final area I will address is operations.

The second automated OraQuick^® production line mentioned on prior calls has been installed and validated and the related regulatory submissions have been made. We expect to begin producing product later in Q2 with this equipment. This will add additional capacity of up to 10.4 million devices per year when this equipment becomes fully operational.

We also plan to order a third automated line this quarter. We estimate this third line will become operational in the back half of 2018 and would add up to an additional 10.4 million devices of annual capacity.

We are also expanding capacity at our OraQuick^® assembly contractor in Thailand. We use this firm to assemble and supply non-US and non-CE marked OraQuick^® product primarily in developing countries. We expect installation and validation of an additional semi-automated assembly line to be completed in 2017, with related regulatory approvals obtained in early 2018. An additional line is also planned for 2018.

11

Given the growth in our molecular business, we are also expanding production capacity. Two additional automated assembly lines have been ordered, which will more than double our capacity. We expect the first line to become operational by the end of 2017 and the second in early 2018.

These changes will help ensure that we have more than enough capacity to meet forecasted global demand for our HIV, HCV and molecular products through at least 2019.

Lastly, as noted on the prior call, we are working with a consulting firm to help us optimize the global footprint for the manufacture of our products. We expect this engagement will conclude in the next several months.

Conclusion

So, in summary, there is much for which to be excited. Our business has more opportunity than at any time since I have been with OraSure. That opportunity is translating into strong financial results as evidenced by our recent quarters. Our international HCV and HIV products and our molecular business continue to fuel strong growth and we are taking the necessary steps to ensure we can meet future demand for our products on a worldwide basis. We believe the recent trends in our businesses will continue and should make 2017 a very successful year for OraSure.

And with that, I will now open the floor to your questions. Operator, please proceed.

* * * *

[Q&A session]

Final Conclusion – Doug Michels

Thank you for participating on today’s call and for your continued interest in OraSure. Have a good afternoon and evening.

12

Important Information

This document contains certain forward-looking statements, including with respect to expected revenues and earnings/loss per share. Forward-looking statements are not guarantees of future performance or results. Known and unknown factors that could cause actual performance or results to be materially different from those expressed or implied in these statements include, but are not limited to ability to market and sell products, whether through our internal, direct sales force or third parties; ability to manufacture products in accordance with applicable specifications, performance standards and quality requirements; ability to obtain, and timing and cost of obtaining, necessary regulatory approvals for new products or new indications or applications for existing products; ability to comply with applicable regulatory requirements; ability to effectively resolve warning letters, audit observations and other findings or comments from the FDA or other regulators; changes in relationships, including disputes or disagreements, with strategic partners or other parties and reliance on strategic partners for the performance of critical activities under collaborative arrangements; impact of increased reliance on U.S. government contracts; failure of distributors or other customers to meet purchase forecasts, historic purchase levels or minimum purchase requirements for our products; impact of replacing distributors; inventory levels at distributors and other customers; ability of the Company to achieve its financial and strategic objectives and continue to increase its revenues, including the ability to expand international sales; ability to identify, complete, integrate and realize the full benefits of future acquisitions; impact of competitors, competing products and technology changes; impact of negative economic conditions, high unemployment levels and poor credit conditions; reduction or deferral of public funding available to customers; competition from new or better technology or lower cost products; ability to develop, commercialize and market new products; market acceptance of oral fluid testing or other products; changes in market acceptance of products based on product performance or other factors, including changes in testing guidelines, algorithms or other recommendations by the Centers for Disease Control and Prevention (“CDC”) or other agencies; ability to fund research and

13

development and other products and operations; ability to obtain and maintain new or existing product distribution channels; reliance on sole supply sources for critical products and components; availability of related products produced by third parties or products required for use of our products; history of losses and ability to achieve sustained profitability; ability to utilize net operating loss carry forwards or other deferred tax assets; volatility of the Company’s stock price; uncertainty relating to patent protection and potential patent infringement claims; uncertainty and costs of litigation relating to patents and other intellectual property; availability of licenses to patents or other technology; ability to enter into international manufacturing agreements; obstacles to international marketing and manufacturing of products; ability to sell products internationally, including the impact of changes in international funding sources and testing algorithms; adverse movements in foreign currency exchange rates; loss or impairment of sources of capital; ability to meet financial covenants in credit agreements; ability to attract and retain qualified personnel; exposure to product liability and other types of litigation; changes in international, federal or state laws and regulations; customer consolidations and inventory practices; equipment failures and ability to obtain needed raw materials and components; the impact of terrorist attacks and civil unrest; and general political, business and economic conditions. These and other factors are discussed more fully in our Securities and Exchange Commission (“SEC”) filings, including our registration statements, Annual Report on Form 10-K for the year ended December 31, 2016, Quarterly Reports on Form 10-Q, and other filings with the SEC. Although forward-looking statements help to provide information about future prospects, readers should keep in mind that forward-looking statements may not be reliable. The forward-looking statements are made as of the date of this call, and we undertake no duty to update these statements.

14